218 related articles for article (PubMed ID: 17925410)
21. Determining the impact of culture on venous thromboembolism prevention in trauma patients: A Southwestern Surgical Congress Multicenter trial.
Regner JL; Shaver CN;
Am J Surg; 2019 Jun; 217(6):1030-1036. PubMed ID: 30503515
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
[TBL] [Abstract][Full Text] [Related]
23. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline.
Lederle FA; Zylla D; MacDonald R; Wilt TJ
Ann Intern Med; 2011 Nov; 155(9):602-15. PubMed ID: 22041949
[TBL] [Abstract][Full Text] [Related]
24. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
Laporte S; Liotier J; Bertoletti L; Kleber FX; Pineo GF; Chapelle C; Moulin N; Mismetti P
J Thromb Haemost; 2011 Mar; 9(3):464-72. PubMed ID: 21232002
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
[TBL] [Abstract][Full Text] [Related]
26. Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke.
Hackett CT; Ramanathan RS; Malhotra K; Quigley MR; Kelly KM; Tian M; Protetch J; Wong C; Wright DG; Tayal AH
Thromb Res; 2015 Feb; 135(2):249-54. PubMed ID: 25554497
[TBL] [Abstract][Full Text] [Related]
27. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
Harrington DW
Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
[TBL] [Abstract][Full Text] [Related]
28. The incidence and risk factors of recurrent venous thromboembolism during pregnancy.
Galambosi PJ; Ulander VM; Kaaja RJ
Thromb Res; 2014 Aug; 134(2):240-5. PubMed ID: 24835671
[TBL] [Abstract][Full Text] [Related]
29. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
Wein L; Wein S; Haas SJ; Shaw J; Krum H
Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
[TBL] [Abstract][Full Text] [Related]
31. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
32. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.
Turpie AG; Norris TM
Thromb Haemost; 2004 Jul; 92(1):3-12. PubMed ID: 15213839
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Gritsiouk Y; Hegsted DA; Schlesinger P; Gardiner SK; Gubler KD
Am J Surg; 2014 May; 207(5):648-51; discussion 651-2. PubMed ID: 24560359
[TBL] [Abstract][Full Text] [Related]
34. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials.
Chapelle C; Rosencher N; Jacques Zufferey P; Mismetti P; Cucherat M; Laporte S;
Arthroscopy; 2014 Aug; 30(8):987-96. PubMed ID: 24813323
[TBL] [Abstract][Full Text] [Related]
35. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.
Marchena PJ; Nieto JA; Guil M; García-Bragado F; Rabuñal R; Boccalon H; Trujillo-Santos J; Monreal M;
Thromb Haemost; 2012 Jan; 107(1):37-43. PubMed ID: 22116496
[TBL] [Abstract][Full Text] [Related]
36. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
37. Low Molecular Weight Heparin Is Superior for Venous Thromboembolism Prophylaxis in High-Risk Geriatric Patients.
Deusenberry CM; Bardsley C; Sharon M; Hobbs GR; Wilson AM; Bardes JM
Am Surg; 2023 Dec; 89(12):5837-5841. PubMed ID: 37208855
[TBL] [Abstract][Full Text] [Related]
38. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients.
Spyropoulos AC
Chest; 2005 Aug; 128(2):958-69. PubMed ID: 16100192
[TBL] [Abstract][Full Text] [Related]
39. Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Yi X; Lin J; Wang C; Zhang B; Chi W
J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1537-44. PubMed ID: 24656240
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
